A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine
NCT ID: NCT00169481
Last Updated: 2017-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
689 participants
INTERVENTIONAL
2004-10-31
2005-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule
NCT00307034
Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
NCT00307541
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
NCT00334334
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age
NCT00489554
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
NCT00344318
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pneumococcal (vaccine)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Planned administration/ administration of a licensed vaccine not foreseen by the study protocol during the period starting from 30 days before the first dose of vaccine(s) and ending 30 days after the last dose.
8 Weeks
16 Weeks
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Bad Saulgau, Baden-Wurttemberg, Germany
GSK Investigational Site
Bretten, Baden-Wurttemberg, Germany
GSK Investigational Site
Eppelheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Ettenheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Kehl, Baden-Wurttemberg, Germany
GSK Investigational Site
Oberkirch, Baden-Wurttemberg, Germany
GSK Investigational Site
Offenburg, Baden-Wurttemberg, Germany
GSK Investigational Site
Schwäbisch Hall, Baden-Wurttemberg, Germany
GSK Investigational Site
Stuttgart, Baden-Wurttemberg, Germany
GSK Investigational Site
Tauberbischofsheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Cham, Bavaria, Germany
GSK Investigational Site
Herzogenaurach, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Nördlingen, Bavaria, Germany
GSK Investigational Site
Olching, Bavaria, Germany
GSK Investigational Site
Weilheim, Bavaria, Germany
GSK Investigational Site
Zwiesel, Bavaria, Germany
GSK Investigational Site
Hamburg, City state of Hamburg, Germany
GSK Investigational Site
Koenigstein, Hesse, Germany
GSK Investigational Site
Marburg/Lahn, Hesse, Germany
GSK Investigational Site
Wiesbaden, Hesse, Germany
GSK Investigational Site
Salzgitter, Lower Saxony, Germany
GSK Investigational Site
Wolfenbüttel, Lower Saxony, Germany
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany
GSK Investigational Site
Waren, Mecklenburg-Vorpommern, Germany
GSK Investigational Site
Bochum, North Rhine-Westphalia, Germany
GSK Investigational Site
Detmold, North Rhine-Westphalia, Germany
GSK Investigational Site
Dortmund, North Rhine-Westphalia, Germany
GSK Investigational Site
Erkrath, North Rhine-Westphalia, Germany
GSK Investigational Site
Heiligenhaus, North Rhine-Westphalia, Germany
GSK Investigational Site
Kleve-Materborn, North Rhine-Westphalia, Germany
GSK Investigational Site
Krefeld, North Rhine-Westphalia, Germany
GSK Investigational Site
Löhne, North Rhine-Westphalia, Germany
GSK Investigational Site
Münster, North Rhine-Westphalia, Germany
GSK Investigational Site
Bodenheim, Rhineland-Palatinate, Germany
GSK Investigational Site
Frankenthal, Rhineland-Palatinate, Germany
GSK Investigational Site
Ludwigshafen am Rhein, Rhineland-Palatinate, Germany
GSK Investigational Site
Mainz, Rhineland-Palatinate, Germany
GSK Investigational Site
Schoeneberg - Kuebelberg, Rhineland-Palatinate, Germany
GSK Investigational Site
Trier, Rhineland-Palatinate, Germany
GSK Investigational Site
Trier, Rhineland-Palatinate, Germany
GSK Investigational Site
Worms, Rhineland-Palatinate, Germany
GSK Investigational Site
Bredstedt, Schleswig-Holstein, Germany
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany
GSK Investigational Site
Husum, Schleswig-Holstein, Germany
GSK Investigational Site
Neumünster, Schleswig-Holstein, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Bad Lobenstein, Thuringia, Germany
GSK Investigational Site
Weimar, Thuringia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
103488
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.